Cargando…

Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension

INTRODUCTION: Milrinone at inotropic doses requires the addition of a vasoconstrictive drug. We hypothesized that terlipressin use could selectively recover the systemic vascular hypotension induced by milrinone without increasing the pulmonary vascular resistance (PVR) and mean pulmonary artery pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelazziz, Mai Mohsen, Abdelhamid, Hadil Magdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489405/
https://www.ncbi.nlm.nih.gov/pubmed/30971593
http://dx.doi.org/10.4103/aca.ACA_83_18
_version_ 1783414820888903680
author Abdelazziz, Mai Mohsen
Abdelhamid, Hadil Magdi
author_facet Abdelazziz, Mai Mohsen
Abdelhamid, Hadil Magdi
author_sort Abdelazziz, Mai Mohsen
collection PubMed
description INTRODUCTION: Milrinone at inotropic doses requires the addition of a vasoconstrictive drug. We hypothesized that terlipressin use could selectively recover the systemic vascular hypotension induced by milrinone without increasing the pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (MPAP) as norepinephrine in cardiac surgery patients. PATIENTS AND METHODS: Patients with pulmonary hypertension were enrolled in this study. At the start of rewarming a milrinone 25 μg/kg bolus over 10 min followed by infusion at the rate of 0.25 μg/kg/min. Just after the loading dose of milrinone, the patients were randomized to receive norepinephrine infusion at a dose of 0.1 μg/kg/min (norepinephrine group) or terlipressin infusion at a dose of 2 μg/kg/h (terlipressin group). Heart rate, mean arterial blood pressure (MAP), central venous pressure, MPAP, systemic vascular resistance (SVR), PVR, cardiac output were measured after induction of anesthesia, after loading dose of milrinone, during skin closure, and in the intensive care unit till 24 h. RESULTS: Milrinone decreased MAP (from 79.56 ± 4.5 to 55.21 ± 2.1 and from 78.46 ± 3.3 to 54.11 ± 1.1) and decreased the MPAP (from 59.5 ± 3.5 to 25.4 ± 2.6 and from 61.3 ± 5.2 to 25.1 ± 2.3) in both groups. After norepinephrine, there was an increase in the MAP which is comparable to terlipressin group (P > 0.05). Terlipressin group shows a significant lower MPAP than norepinephrine group (24.5 ± 1.4 at skin closure vs. 43.3 ± 2.1, than 20.3 ± 2.1 at 24 h vs. 39.8 ± 3.8 postoperatively). There is a comparable increase in the SVR in both group, PVR showed a significant increase in the norepinephrine group compared to the terlipressin group (240.5 ± 23 vs. 140.6 ± 13 at skin closure than 190.3 ± 32 vs. 120.3 ± 10 at 24 h postoperatively). CONCLUSION: The use of terlipressin after milrinone will reverse systemic hypotension with lesser effect on the pulmonary artery pressure.
format Online
Article
Text
id pubmed-6489405
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-64894052019-05-03 Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension Abdelazziz, Mai Mohsen Abdelhamid, Hadil Magdi Ann Card Anaesth Original Article INTRODUCTION: Milrinone at inotropic doses requires the addition of a vasoconstrictive drug. We hypothesized that terlipressin use could selectively recover the systemic vascular hypotension induced by milrinone without increasing the pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (MPAP) as norepinephrine in cardiac surgery patients. PATIENTS AND METHODS: Patients with pulmonary hypertension were enrolled in this study. At the start of rewarming a milrinone 25 μg/kg bolus over 10 min followed by infusion at the rate of 0.25 μg/kg/min. Just after the loading dose of milrinone, the patients were randomized to receive norepinephrine infusion at a dose of 0.1 μg/kg/min (norepinephrine group) or terlipressin infusion at a dose of 2 μg/kg/h (terlipressin group). Heart rate, mean arterial blood pressure (MAP), central venous pressure, MPAP, systemic vascular resistance (SVR), PVR, cardiac output were measured after induction of anesthesia, after loading dose of milrinone, during skin closure, and in the intensive care unit till 24 h. RESULTS: Milrinone decreased MAP (from 79.56 ± 4.5 to 55.21 ± 2.1 and from 78.46 ± 3.3 to 54.11 ± 1.1) and decreased the MPAP (from 59.5 ± 3.5 to 25.4 ± 2.6 and from 61.3 ± 5.2 to 25.1 ± 2.3) in both groups. After norepinephrine, there was an increase in the MAP which is comparable to terlipressin group (P > 0.05). Terlipressin group shows a significant lower MPAP than norepinephrine group (24.5 ± 1.4 at skin closure vs. 43.3 ± 2.1, than 20.3 ± 2.1 at 24 h vs. 39.8 ± 3.8 postoperatively). There is a comparable increase in the SVR in both group, PVR showed a significant increase in the norepinephrine group compared to the terlipressin group (240.5 ± 23 vs. 140.6 ± 13 at skin closure than 190.3 ± 32 vs. 120.3 ± 10 at 24 h postoperatively). CONCLUSION: The use of terlipressin after milrinone will reverse systemic hypotension with lesser effect on the pulmonary artery pressure. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6489405/ /pubmed/30971593 http://dx.doi.org/10.4103/aca.ACA_83_18 Text en Copyright: © 2019 Annals of Cardiac Anaesthesia http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Abdelazziz, Mai Mohsen
Abdelhamid, Hadil Magdi
Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title_full Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title_fullStr Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title_full_unstemmed Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title_short Terlipressin versus Norepinephrine to Prevent Milrinone-Induced Systemic Vascular Hypotension in Cardiac Surgery Patient with Pulmonary Hypertension
title_sort terlipressin versus norepinephrine to prevent milrinone-induced systemic vascular hypotension in cardiac surgery patient with pulmonary hypertension
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489405/
https://www.ncbi.nlm.nih.gov/pubmed/30971593
http://dx.doi.org/10.4103/aca.ACA_83_18
work_keys_str_mv AT abdelazzizmaimohsen terlipressinversusnorepinephrinetopreventmilrinoneinducedsystemicvascularhypotensionincardiacsurgerypatientwithpulmonaryhypertension
AT abdelhamidhadilmagdi terlipressinversusnorepinephrinetopreventmilrinoneinducedsystemicvascularhypotensionincardiacsurgerypatientwithpulmonaryhypertension